{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:04:34Z","timestamp":1793412274711,"version":"4.5.0"},"reference-count":186,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jaad.2025.01.086","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T12:05:22Z","timestamp":1738670722000},"page":"1337-1350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Bullous pemphigoid: A practical approach to diagnosis and management in the modern era"],"prefix":"10.1016","volume":"92","author":[{"given":"Camille M.","family":"Powers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sach","family":"Thakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Talia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Dubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Zone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna A.","family":"Culton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-6159","authenticated-orcid":false,"given":"Jonas A.","family":"Adalsteinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clindermatol.2010.07.010","article-title":"Autoimmune blistering diseases in the elderly","volume":"29","author":"Parker","year":"2011","journal-title":"Clin Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2025.01.086_bib2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/archderm.134.9.1075","article-title":"Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group","volume":"134","author":"Vaillant","year":"1998","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib3","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2133.2012.11108.x","article-title":"Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort","volume":"167","author":"della Torre","year":"2012","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/bjd.12072","article-title":"British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012","volume":"167","author":"Venning","year":"2012","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.01.086_bib5","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/jamadermatol.2013.756","article-title":"Bullous pemphigoid as pruritus in the elderly: a common presentation","volume":"149","author":"Bakker","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"9863","key":"10.1016\/j.jaad.2025.01.086_bib6","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib7","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1159\/000515954","article-title":"Non-bullous pemphigoid: a single-center retrospective study","volume":"237","author":"Moar","year":"2021","journal-title":"Dermatology"},{"issue":"10","key":"10.1016\/j.jaad.2025.01.086_bib8","first-page":"2856","article-title":"A review of the immunologic pathways involved in bullous pemphigoid and novel therapeutic targets","volume":"11","author":"Afarideh","year":"2022","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.jaad.2025.01.086_bib9","article-title":"New-onset or flare-up of bullous pemphigoid associated with COVID-19 vaccines: a systematic review of case report and case series studies","volume":"11","author":"Ghanaatpisheh","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"15","key":"10.1016\/j.jaad.2025.01.086_bib10","doi-asserted-by":"crossref","first-page":"adv00224","DOI":"10.2340\/00015555-3457","article-title":"A systematic review of drug-induced pemphigoid","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"10.1016\/j.jaad.2025.01.086_bib11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamadermatol.2020.1587","article-title":"Association between medication use and bullous pemphigoid: a systematic review and meta-analysis","volume":"156","author":"Liu","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.01.086_bib12","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3389\/fimmu.2019.01238","article-title":"Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid","volume":"10","author":"Tasanen","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaad.2022.02.036","article-title":"Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: results of a multicenter study","volume":"87","author":"Salemme","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database","volume":"175","author":"B\u00e9n\u00e9","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/bjd.21836","article-title":"Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study","volume":"187","author":"Kawsar","year":"2022","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib16","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/biomedicines11020323","article-title":"A review of bullous dermatologic adverse events associated with anti-cancer therapy","volume":"11","author":"Parisi","year":"2023","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib18","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/bjd.19313","article-title":"Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: a cross-sectional study","volume":"183","author":"Molina","year":"2020","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.01.086_bib19","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1111\/jdv.17253","article-title":"Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1\/PD-L1 therapy: a national retrospective study","volume":"35","author":"Juzot","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/jdv.17855","article-title":"European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force \u201cDermatology for cancer patients\u201d position statement","volume":"36","author":"Apalla","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.jaad.2025.01.086_bib21","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib22","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"issue":"23","key":"10.1016\/j.jaad.2025.01.086_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316786","article-title":"From molecular insights to clinical perspectives in drug-associated bullous pemphigoid","volume":"24","author":"de Nicolas-Ruanes","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib24","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2019.12.059","article-title":"Missed drug-induced bullous pemphigoid leads to longer immunosuppression than recognized cases: a 9-year retrospective review","volume":"82","author":"Molina","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib25","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/j.jaad.2020.04.178","article-title":"Missed induced bullous pemphigoid: when the anamnesis is the cure","volume":"83","author":"Chessa","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.iac.2012.04.002","article-title":"Clinical features and practical diagnosis of bullous pemphigoid","volume":"32","author":"Schmidt","year":"2012","journal-title":"Immunol Allergy Clin North Am"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib27","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/jamadermatol.2018.5049","article-title":"Assessment of the prevalence of mucosal involvement in bullous pemphigoid","volume":"155","author":"Kridin","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.01.086_bib28","article-title":"Risk factors for mucosal involvement in bullous pemphigoid and the possible mechanism: a review","volume":"8","author":"Chen","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.jaad.2025.01.086_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2014incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.jaad.2025.01.086_bib30","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jaad.2014.02.030","article-title":"Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009","volume":"71","author":"Brick","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib32","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/bjd.13189","article-title":"Increasing incidence of bullous pemphigoid in Northern Finland: a retrospective database study in Oulu University Hospital","volume":"171","author":"F\u00f6rsti","year":"2014","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib33","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2005.06662.x","article-title":"Annual incidence and mortality of bullous pemphigoid in the grampian region of North-East Scotland","volume":"153","author":"Gudi","year":"2005","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2015.06.033","article-title":"Skin biopsy: biopsy issues in specific diseases","volume":"74","author":"Elston","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2025.01.086_bib35","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archdermatol.2009.205","article-title":"Mortality of bullous skin disorders from 1979 through 2002 in the United States","volume":"145","author":"Risser","year":"2009","journal-title":"Arch Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2025.01.086_bib36","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/jamadermatol.2023.3121","article-title":"Skin-related quality of life during autoimmune bullous disease course","volume":"159","author":"Hopkins","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib37","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/bjd.12806","article-title":"Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the National Skin Centre","volume":"170","author":"Cai","year":"2014","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib38","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jaad.2015.01.029","article-title":"Infectious complications in bullous pemphigoid: an analysis of risk factors","volume":"72","author":"Phoon","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00403-018-1875-z","article-title":"Mortality and risk factors among Israeli bullous pemphigoid patients","volume":"311","author":"Rozenblat","year":"2019","journal-title":"Arch Derm Res"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.086_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264705","article-title":"Prognostic factors for mortality in bullous pemphigoid: a systematic review and meta-analysis","volume":"17","author":"Chen","year":"2022","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.jaad.2025.01.086_bib41","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00403-017-1772-x","article-title":"Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in Poland","volume":"309","author":"Kalinska-Bienias","year":"2017","journal-title":"Arch Derm Res"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.086_bib42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/bjd\/ljae219","article-title":"Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids","volume":"191","author":"Kridin","year":"2024","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.086_bib43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archderm.134.4.465","article-title":"High risk of death in elderly patients with extensive bullous pemphigoid","volume":"134","author":"Roujeau","year":"1998","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/jalm\/jfab147","article-title":"Diagnostics for dermatologic diseases with autoantibodies","volume":"7","author":"Leiferman","year":"2022","journal-title":"J Appl Lab Med"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib45","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaad.2016.11.002","article-title":"Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseases","volume":"76","author":"van Beek","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-7-49","article-title":"Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy","volume":"7","author":"van Beek","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1046\/j.1365-2230.2003.01419.x","article-title":"Comparison of immunofluorescence microscopy, immunoblotting and enzyme-linked immunosorbent assay methods in the laboratory diagnosis of bullous pemphigoid","volume":"28","author":"Chan","year":"2003","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/jdv.15770","article-title":"Validation of the BIOCHIP test for the diagnosis of bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus","volume":"34","author":"Yang","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.01.086_bib49","doi-asserted-by":"crossref","DOI":"10.5402\/2012\/237802","article-title":"Biochip technology for the serological diagnosis of bullous pemphigoid","volume":"2012","author":"Zarian","year":"2012","journal-title":"ISRN Dermatol"},{"key":"10.1016\/j.jaad.2025.01.086_bib50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/CCID.S324331","article-title":"Patient quality of life improvement in bullous disease: a review of primary literature and considerations for the clinician","volume":"15","author":"Padniewski","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"18","key":"10.1016\/j.jaad.2025.01.086_bib51","first-page":"adv00320","article-title":"Characteristics of pruritus in bullous pemphigoid and impact on quality of life: a prospective cohort study","volume":"100","author":"Briand","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"10.1016\/j.jaad.2025.01.086_bib52","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamadermatol.2013.4972","article-title":"Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire: the autoimmune bullous disease quality of life questionnaire","volume":"149","author":"Sebaratnam","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2025.01.086_bib53","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s11136-015-0965-z","article-title":"Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA","volume":"24","author":"Sebaratnam","year":"2015","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/120347540100500202","article-title":"Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases","volume":"5","author":"Chren","year":"2001","journal-title":"J Cutan Med Surg"},{"issue":"9","key":"10.1016\/j.jaad.2025.01.086_bib55","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jclinepi.2015.03.023","article-title":"Pragmatic characteristics of patient-reported outcome measures are important for use in clinical practice","volume":"68","author":"Kroenke","year":"2015","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib56","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jid.2022.01.008","article-title":"Incorporating patient-reported outcomes as a vital sign for dermatologic clinical care and clinical investigations","volume":"142","author":"Secrest","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.086_bib57","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/bjd.18027","article-title":"Benefits to patient care of electronically capturing patient-reported outcomes in dermatology","volume":"181","author":"Secrest","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.01.086_bib58","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fmed.2018.00238","article-title":"Comorbidities and treatment strategies in bullous pemphigoid: an appraisal of the existing litterature","volume":"5","author":"Bech","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.jaad.2025.01.086_bib59","doi-asserted-by":"crossref","first-page":"adv5329","DOI":"10.2340\/actadv.v103.5329","article-title":"Risk of serious infections in patients with bullous pemphigoid: a population-based cohort study","volume":"103","author":"Chang","year":"2023","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib60","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jaad.2025.01.086_bib61","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/jid.2008.412","article-title":"A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study","volume":"129","author":"Joly","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib62","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000324899","article-title":"Management of bullous pemphigoid with topical steroids in the clinical practice of a single center: outcome at 6 and 12 months","volume":"222","author":"Ingen-Housz-Oro","year":"2011","journal-title":"Dermatology"},{"issue":"10","key":"10.1016\/j.jaad.2025.01.086_bib63","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib64","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.annder.2021.08.005","article-title":"Updated French guidelines for the therapeutic management of bullous pemphigoid","volume":"149","author":"Castel","year":"2022","journal-title":"Ann Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib65","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/ced.14161","article-title":"Serum triamcinolone levels during intensive, inpatient wet-dressing therapy","volume":"45","author":"Mirza","year":"2020","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib66","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaad.2011.06.025","article-title":"Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic","volume":"67","author":"Dabade","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib67","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2133.1989.tb07769.x","article-title":"Dapsone as first line therapy for bullous pemphigoid","volume":"120","author":"Venning","year":"1989","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib68","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1001\/archderm.1977.01640050070009","article-title":"Bullous pemphigoid responding to sulfapyridine and the sulfones","volume":"113","author":"Person","year":"1977","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.086_bib69","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0190-9622(96)80085-5","article-title":"Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases","volume":"34","author":"Bouscarat","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib70","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/bjd.15649","article-title":"An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone","volume":"177","author":"Sticherling","year":"2017","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib71","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.aller.2010.12.009","article-title":"Efficacy and safety of azathioprine and dapsone as an adjuvant in the treatment of bullous pemphigoid","volume":"40","author":"Tirado-S\u00e1nchez","year":"2012","journal-title":"Allergol Immunopathol"},{"issue":"7","key":"10.1016\/j.jaad.2025.01.086_bib72","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/archderm.144.7.946-a","article-title":"Comparative effectiveness of azathioprine or mycophenolate mofetil as an adjuvant for the treatment of bullous pemphigoid","volume":"144","author":"Bystryn","year":"2008","journal-title":"Arch Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.01.086_bib73","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00002512-200825080-00001","article-title":"Role of methotrexate in the treatment of bullous pemphigoid in the elderly","volume":"25","author":"Patton","year":"2008","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib74","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","journal-title":"J Dermatol Sci"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.36849\/JDD.6042","article-title":"The use of mycophenolate mofetil in the treatment of bullous pemphigoid","volume":"21","author":"Liang","year":"2022","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib76","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2025.01.086_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21100","volume":"21","author":"Chalmers","year":"2017","journal-title":"Health Technol Assess"},{"issue":"10079","key":"10.1016\/j.jaad.2025.01.086_bib78","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(17)30549-4","article-title":"Doxycycline: a first-line treatment for bullous pemphigoid?","volume":"389","author":"Grantham","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib79","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/09546630260199514","article-title":"Successful treatment with doxycycline and nicotinamide of two cases of persistent pemphigoid gestationis","volume":"13","author":"Amato","year":"2002","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"10.1016\/j.jaad.2025.01.086_bib80","first-page":"327","article-title":"Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore","volume":"41","author":"Goon","year":"2000","journal-title":"Singapore Med J"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib81","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archderm.1994.01690060083010","article-title":"Nicotinamide and tetracycline therapy of bullous pemphigoid","volume":"130","author":"Fivenson","year":"1994","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib82","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/archderm.144.5.658","article-title":"Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies","volume":"144","author":"Czernik","year":"2008","journal-title":"Arch Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.01.086_bib83","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/exd.14829","article-title":"A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: special focus on indication and combination therapy","volume":"32","author":"Kianfar","year":"2023","journal-title":"Exp Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.086_bib84","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaad.2015.11.030","article-title":"Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: a retrospective study with a 6-year follow-up","volume":"74","author":"Ahmed","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"23","key":"10.1016\/j.jaad.2025.01.086_bib85","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2025.01.086_bib86","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/DDDT.S41645","article-title":"Rituximab for the treatment of rheumatoid arthritis: an update","volume":"8","author":"Mok","year":"2013","journal-title":"Drug Des Devel Ther"},{"issue":"24","key":"10.1016\/j.jaad.2025.01.086_bib87","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib88","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/bjd.18482","article-title":"Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br J Dermatol"},{"issue":"10083","key":"10.1016\/j.jaad.2025.01.086_bib89","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib90","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients","volume":"65","author":"Kasperkiewicz","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib91","doi-asserted-by":"crossref","first-page":"T62","DOI":"10.1016\/j.ad.2021.10.024","article-title":"Low-dose rituximab for bullous pemphigoid. Protocol and single-center experience","volume":"114","author":"Su\u00e1rez-Caranto\u00f1a","year":"2023","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib92","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjd.13633","article-title":"First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid","volume":"173","author":"Cho","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib93","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaad.2019.03.049","article-title":"Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients","volume":"81","author":"Polansky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.01.086_bib94","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib95","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jdermsci.2013.11.014","article-title":"Rituximab decreases without preference all subclasses of IgG anti-BP180 autoantibodies in refractory bullous pemphigoid (BP)","volume":"74","author":"Ronaghy","year":"2014","journal-title":"J Dermatol Sci"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib96","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjd.19890","article-title":"Mortality and clinical response of patients with bullous pemphigoid treated with rituximab","volume":"185","author":"Yoo","year":"2021","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2025.01.086_bib97","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors associated with complete remission after rituximab therapy for pemphigus","volume":"155","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.01.086_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103357","article-title":"Effect of body mass index on treatment response of biologic\/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review","volume":"22","author":"Gialouri","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib99","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","article-title":"Rituximab in autoimmune bullous diseases: mixed responses and adverse effects","volume":"156","author":"Schmidt","year":"2007","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib100","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jaad.2019.11.023","article-title":"Clinical outcome and safety of rituximab therapy for pemphigoid diseases","volume":"82","author":"Tovanabutra","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib101","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jaad.2021.06.862","article-title":"The safety of rituximab for the treatment of autoimmune blistering diseases: a systematic review","volume":"86","author":"Mohammed","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.01.086_bib103","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2025.01.086_bib104","article-title":"Bullous pemphigoid: the role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jaad.2025.01.086_bib105","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of dupilumab in patients with bullous pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib106","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib107","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/bjd\/ljad136","article-title":"Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients","volume":"189","author":"Moghadam","year":"2023","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib108","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/1346-8138.16652","article-title":"Pruritogens in pemphigoid diseases: possible therapeutic targets for a burdensome symptom","volume":"50","author":"Hiroyasu","year":"2023","journal-title":"J Dermatol"},{"issue":"24","key":"10.1016\/j.jaad.2025.01.086_bib109","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib110","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jaip.2022.12.018","article-title":"No association between dupilumab use and short-term cancer development in atopic dermatitis patients","volume":"11","author":"Owji","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2025.01.086_bib111","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jdcr.2023.08.013","article-title":"Pemphigoid gestationis treated with dupilumab","volume":"41","author":"Chen","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib112","first-page":"e752","article-title":"Successful therapy of pemphigoid gestationis with dupilumab-A new case","volume":"37","author":"Alvarez Martinez","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib114","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaci.2004.11.053","article-title":"The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation","volume":"115","author":"Holgate","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib115","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/bjd\/ljad369","article-title":"Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients","volume":"190","author":"Chebani","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.01.086_bib116","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/ced\/llae067","article-title":"Efficacy of omalizumab for the treatment of bullous pemphigoid. Spanish multicenter real-world experience","volume":"49","author":"Aguado V\u00e1zquez","year":"2024","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib117","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamadermatol.2023.4508","article-title":"Rituximab and omalizumab combination therapy for bullous pemphigoid","volume":"160","author":"Le","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib118","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.jaci.2017.07.013","article-title":"Anaphylaxis associated with omalizumab administration: risk factors and patient characteristics","volume":"140","author":"Lieberman","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib119","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force report on omalizumab-associated anaphylaxis","volume":"120","author":"Cox","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.jaad.2025.01.086_bib120","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.3390\/cancers11122002","article-title":"JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression","volume":"11","author":"Owen","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaad.2025.01.086_bib121","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6716419","article-title":"Expression of the JAK\/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis","volume":"2017","author":"Juczynska","year":"2017","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jaad.2025.01.086_bib122","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.940966","article-title":"Upadacitinib as a rescue therapy in acute severe ulcerative colitis: a case report and review of the literature","volume":"24","author":"Ali","year":"2023","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.jaad.2025.01.086_bib123","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jdcr.2022.12.006","article-title":"Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib","volume":"32","author":"Nash","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib124","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1111\/jdv.19475","article-title":"Abrocitinib-A promising option for patients with refractory bullous pemphigoid","volume":"38","author":"Jiang","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib125","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/bjd\/ljac078","article-title":"Tofacitinib in recalcitrant bullous pemphigoid: a report of seven cases","volume":"188","author":"Fan","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.01.086_bib126","article-title":"Janus kinase inhibitors in autoimmune bullous diseases","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.086_bib127","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1159\/000518541","article-title":"Efficacy and safety of Janus kinase inhibitors for the treatment of atopic dermatitis: a systematic review and meta-analysis","volume":"238","author":"Li","year":"2022","journal-title":"Dermatology"},{"issue":"10","key":"10.1016\/j.jaad.2025.01.086_bib128","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15754","article-title":"Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib","volume":"35","author":"Xiao","year":"2022","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jamadermatol.2021.5125","article-title":"Risk of all-cause mortality, cardiovascular disease mortality, and cancer mortality in patients with bullous pemphigoid","volume":"158","author":"Shen","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.086_bib130","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib131","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamadermatol.2023.5509","article-title":"Short-term cardiovascular complications in dermatology patients receiving JAK-STAT inhibitors: a meta-analysis of randomized clinical trials","volume":"160","author":"Ireland","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib132","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13075-024-03358-x","article-title":"Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial","volume":"26","author":"van Vollenhoven","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.jaad.2025.01.086_bib133","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s13555-024-01243-8","article-title":"Practical recommendations on laboratory monitoring in patients with atopic dermatitis on oral JAK inhibitors","volume":"14","author":"Kirchhof","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"10.1016\/j.jaad.2025.01.086_bib134","article-title":"Interventions for bullous pemphigoid","volume":"8","author":"Singh","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature","volume":"20","author":"Kremer","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.01.086_bib136","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15648","article-title":"Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid","volume":"35","author":"Yang","year":"2022","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib137","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2022.06.1186","article-title":"Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor-induced bullous pemphigoid","volume":"88","author":"Said","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib138","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/bjd\/ljad149","article-title":"Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment","volume":"189","author":"Shipman","year":"2023","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2025.01.086_bib139","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.tips.2018.08.004","article-title":"Kill \u2019Em All: efgartigimod immunotherapy for autoimmune diseases","volume":"39","author":"Bayry","year":"2018","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)","volume":"21","author":"Howard","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jaad.2025.01.086_bib141","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.863095","article-title":"FcRn antagonism leads to a decrease of desmoglein-specific B cells: secondary analysis of a phase 2 study of efgartigimod in pemphigus vulgaris and pemphigus foliaceus","volume":"13","author":"Maho-Vaillant","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.jaad.2025.01.086_bib143","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jaad.2025.01.086_bib144","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1057096","article-title":"Bullous pemphigoid-What do we know about the most recent therapies?","volume":"9","author":"Zeng","year":"2022","journal-title":"Front Med"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40257-023-00832-1","article-title":"Advancements in bullous pemphigoid treatment: a comprehensive pipeline update","volume":"25","author":"Karakioulaki","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2025.01.086_bib146","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/cup.13343","article-title":"The spectrum of histopathologic findings in pemphigoid: avoiding diagnostic pitfalls","volume":"45","author":"Hodge","year":"2018","journal-title":"J Cutan Pathol"},{"issue":"9","key":"10.1016\/j.jaad.2025.01.086_bib147","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1001\/archderm.1984.01650450048015","article-title":"Eosinophilic spongiosis in bullous pemphigoid","volume":"120","author":"Nishioka","year":"1984","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib148","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1001\/jamadermatol.2018.4390","article-title":"Assessment of diagnostic strategy for early recognition of bullous and nonbullous variants of pemphigoid","volume":"155","author":"Meijer","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib149","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2230.1990.tb02139.x","article-title":"Determination of the optimum site for diagnostic biopsy for direct immunofluorescence in bullous pemphigoid","volume":"15","author":"Anstey","year":"1990","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib150","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2310\/7750.2014.14004","article-title":"Biopsy location for direct immunofluorescence in patients with suspected bullous pemphigoid impacts probability of a positive test result","volume":"18","author":"Sladden","year":"2014","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib151","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bjd.12198","article-title":"In a patient with an immunobullous disorder, is transportation of the skin biopsy in normal saline adequate for direct immunofluorescence analysis? A critically appraised topic","volume":"169","author":"Patel","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.01.086_bib152","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-5945-4-10","article-title":"Enhanced diagnostic immunofluorescence using biopsies transported in saline","volume":"4","author":"Vodegel","year":"2004","journal-title":"BMC Dermatol"},{"key":"10.1016\/j.jaad.2025.01.086_bib153","doi-asserted-by":"crossref","DOI":"10.3389\/bjbs.2023.11809","article-title":"Diagnostic techniques in autoimmune blistering diseases","volume":"80","author":"Mee","year":"2023","journal-title":"Br J Biomed Sci"},{"key":"10.1016\/j.jaad.2025.01.086_bib154","series-title":"StatPearls","article-title":"Bullous pemphigoid","author":"Baigrie","year":"2023"},{"issue":"5 Pt 1","key":"10.1016\/j.jaad.2025.01.086_bib155","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0190-9622(84)80459-4","article-title":"Epidermolysis bullosa acquisita--a pemphigoid-like disease","volume":"11","author":"Gammon","year":"1984","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib156","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjd.12308","article-title":"The n- vs. u-serration is a learnable criterion to differentiate pemphigoid from epidermolysis bullosa acquisita in direct immunofluorescence serration pattern analysis","volume":"169","author":"Terra","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.01.086_bib157","doi-asserted-by":"crossref","first-page":"336","DOI":"10.25259\/IJDVL_20_2023","article-title":"Accuracy of serration pattern analysis by direct immunofluorescence in subepidermal autoimmune blistering diseases","volume":"90","author":"Sood","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"9","key":"10.1016\/j.jaad.2025.01.086_bib158","first-page":"1077","article-title":"Diagnosis of autoimmune bullous diseases","volume":"16","author":"van Beek","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"issue":"11","key":"10.1016\/j.jaad.2025.01.086_bib159","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1097\/CM9.0000000000002196","article-title":"Diagnostic values of indirect immunofluorescence using salt-split skin, direct immunofluorescence and BP180 NC16A ELISA on bullous pemphigoid","volume":"135","author":"Li","year":"2022","journal-title":"Chin Med J"},{"issue":"12","key":"10.1016\/j.jaad.2025.01.086_bib160","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1365-4632.2008.03824.x","article-title":"Enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence testing in a bullous pemphigoid and pemphigoid gestationis","volume":"47","author":"Barnadas","year":"2008","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.086_bib161","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4103\/0019-5154.74534","article-title":"Salt split technique: a useful tool in the diagnosis of subepidermal bullous disorders","volume":"55","author":"De","year":"2010","journal-title":"Indian J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2025.01.086_bib162","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid","volume":"136","author":"Izumi","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2025.01.086_bib163","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.3389\/fimmu.2019.01974","article-title":"Serological diagnosis of autoimmune bullous skin diseases","volume":"10","author":"Saschenbrecker","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib164","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamadermatol.2013.5757","article-title":"Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study","volume":"150","author":"Fichel","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib165","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/archdermatol.2009.53","article-title":"Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study","volume":"145","author":"Bernard","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2025.01.086_bib166","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3389\/fimmu.2018.00570","article-title":"Anti-type VII collagen antibodies are identified in a subpopulation of bullous pemphigoid patients with relapse","volume":"9","author":"Giusti","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib167","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clim.2008.04.012","article-title":"Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid","volume":"128","author":"Di Zenzo","year":"2008","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib168","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jamadermatol.2017.5465","article-title":"Clinical and immunological profiles of 14 patients with bullous pemphigoid without IgG autoantibodies to the BP180 NC16A domain","volume":"154","author":"Nakama","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib169","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2012.09.012","article-title":"Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbant assay","volume":"68","author":"Fairley","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib170","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1046\/j.1523-1747.2002.19529.x","article-title":"Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain","volume":"119","author":"Hofmann","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib171","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jaad.2018.06.006","article-title":"Circulating bullous pemphigoid 180 autoantibody can be detected in a wide spectrum of patients with other dermatologic conditions: a cross-sectional study","volume":"80","author":"Liu","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib172","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/1523-1747.ep12338088","article-title":"A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid","volume":"109","author":"Zillikens","year":"1997","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib173","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/archdermatol.2011.21","article-title":"Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid","volume":"147","author":"Roussel","year":"2011","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.086_bib174","first-page":"272","article-title":"Anti-BP180 and anti-BP230 enzyme-linked immunosorbent assays for diagnosis and disease activity tracking of bullous pemphigoid: a prospective cohort study","volume":"39","author":"Chanprapaph","year":"2021","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.086_bib175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5021\/ad.2012.24.1.45","article-title":"Usefulness of enzyme-linked immunosorbent assay using recombinant BP180 and BP230 for serodiagnosis and monitoring disease activity of bullous pemphigoid","volume":"24","author":"Lee","year":"2012","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaad.2025.01.086_bib176","series-title":"Cutaneous biometrics","first-page":"1","article-title":"Autoimmune blistering disease: outcome measures","author":"Bak","year":"2019"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.086_bib177","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2230.2010.04013.x","article-title":"Association between effective dose of prednisolone, alone or in conjunction with other immunosuppressants, and titre of anti-bullous pemphigoid 180 antibody: a retrospective study of 42 cases","volume":"36","author":"Miida","year":"2011","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.086_bib178","doi-asserted-by":"crossref","first-page":"119","DOI":"10.47102\/annals-acadmedsg.V44N4p119","article-title":"Anti-BP180 NC16A IgG titres as an indicator of disease activity and outcome in asian patients with bullous pemphigoid","volume":"44","author":"Cai","year":"2015","journal-title":"Ann Acad Med Singap"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib179","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/07853890.2018.1443346","article-title":"Relapse of bullous pemphigoid: an update on this stubborn clinical problem","volume":"50","author":"Wang","year":"2018","journal-title":"Ann Med"},{"key":"10.1016\/j.jaad.2025.01.086_bib180","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fmed.2018.00139","article-title":"High index values of enzyme-linked immunosorbent assay for BP180 at baseline predict relapse in patients with bullous pemphigoid","volume":"5","author":"Koga","year":"2018","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib181","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archdermatol.2011.23","article-title":"Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients","volume":"147","author":"Charneux","year":"2011","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib182","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0923-1811(02)00109-3","article-title":"BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid","volume":"30","author":"Kobayashi","year":"2002","journal-title":"J Dermatol Sci"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib183","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-4632.2008.03473.x","article-title":"Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid","volume":"47","author":"Feng","year":"2008","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.086_bib184","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jdermsci.2004.10.007","article-title":"Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid","volume":"37","author":"Tsuji-Abe","year":"2005","journal-title":"J Dermatol Sci"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.086_bib185","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archderm.136.2.174","article-title":"Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid","volume":"136","author":"Schmidt","year":"2000","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.086_bib186","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/bjd.16553","article-title":"Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score","volume":"179","author":"Holtsche","year":"2018","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib187","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1684\/ejd.2023.4573","article-title":"IgE anti-BP180 NC16A autoantibody in both serum and blister fluid samples does not correlate with disease activity of bullous pemphigoid","volume":"33","author":"Sun","year":"2023","journal-title":"Eur J Dermatol"},{"issue":"10079","key":"10.1016\/j.jaad.2025.01.086_bib188","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.086_bib189","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1067\/mjd.2001.116337","article-title":"Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment","volume":"45","author":"Ahmed","year":"2001","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225001859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225001859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:02:00Z","timestamp":1777568520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225001859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":186,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0190962225001859"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.01.086","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bullous pemphigoid: A practical approach to diagnosis and management in the modern era","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.01.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}